Keshav, S., Ungashe, S., Zheng, W., Belker, P., Wright, K., & Schall, T. J. (2007). Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease. 132(4), A157–A157.

Keshav, S., et al. Ccx282-B, An Orally Active Inhibitor of Chemokine Receptor Ccr9, Shows Anti-Inflammatory and Clinical Activity in the Treatment of Crohn's Disease. no. 4, 2007, pp. A157–A157.

Keshav, S, S Ungashe, W Zheng, P Belker, K Wright, and TJ Schall. 2007. “Ccx282-B, An Orally Active Inhibitor of Chemokine Receptor Ccr9, Shows Anti-Inflammatory and Clinical Activity in the Treatment of Crohn's Disease.” In , 132:A157–A157.